ANDA Review Improvements Continue As FDA Eyes Generic User Fee Resources
Executive Summary
FDA's review backlog for ANDAs requires a "significant" improvement in resources, Office of Generic Drugs Director Gary Buehler said
You may also be interested in...
Generic Drug Fees In, DTC Fees Dropped, From Obama Budget Proposal
Some of FDA's funding increase promised in President Obama's budget comes from user fees which would have to be established legislatively - meaning that the administration will have to negotiate with industry and congressional authorizing committees, not just House and Senate appropriators, in order to see its vision enacted
Generic Drug Fees In, DTC Fees Dropped, From Obama Budget Proposal
Some of FDA's funding increase promised in President Obama's budget comes from user fees which would have to be established legislatively - meaning that the administration will have to negotiate with industry and congressional authorizing committees, not just House and Senate appropriators, in order to see its vision enacted
Sandoz Gets New Global, U.S. CEOs: Will Flat Regional Structure Spark Growth?
Sandoz's new CEO Jeff George is flattening out the firm's global organization to position sales groups closer to customers, and he's hired former Barr CEO Christine Mundkur to shape up the U.S. operation in reforms aimed at returning the world's second largest generics business to strong growth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: